GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) is currently recruiting participants for a clinical study titled ‘Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-1)’. The study aims to evaluate the efficacy and safety of depemokimab, a biologic treatment for individuals with moderate to severe COPD characterized by type 2 inflammation. This research is significant as it seeks to address the unmet needs of patients with uncontrolled COPD symptoms.
The intervention being tested is depemokimab, an experimental drug administered alongside standard care. It is designed to help manage COPD symptoms by targeting type 2 inflammation, potentially offering a new treatment avenue for patients.
The study follows an interventional design with a randomized, parallel-group model. It is a double-blind trial, meaning neither participants nor researchers know who receives the drug or placebo, ensuring unbiased results. The primary purpose of the study is treatment-focused.
The study began on June 20, 2025, with an initial submission date of April 28, 2025. The latest update was submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and anticipated milestones.
For investors, this study could influence GSK’s stock performance and investor sentiment, especially if depemokimab proves effective. The COPD treatment market is competitive, and a successful outcome could position GSK favorably against its peers.
The study is ongoing, and further details are available on the ClinicalTrials portal.